Relay unrolls early data for anti-FGFR drug it thinks stand alone in terms of safety profile
When Third Rock-backed Relay Therapeutics went public last year, it argued its novel drug design platform could potentially break the code in a range of hard-to-treat tumor types. Now, the biotech’s proof-of-concept drug is reading out early data — and they look competitive.
Relay’s FGFR2 inhibitor RLY-4008 uncorked three confirmed partial responses among six patients with FGFR2 fusion-positive cholangiocarcinoma, a form of bile duct cancer, who had not been previously treated with what are known as “pan-FGFR” inhibitors, according to Phase I data presented Friday at the virtual AACR-NCI-EORTC Molecular Targets Conference.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,500+ biopharma pros reading Endpoints daily — and it's free.